Open AccessRapid Communication: Efavirenz- and Adefovir Dipivoxil–Based Salvage Therapy in Highly Treatment-Experienced Patients: Clinical and Genotypic Predictors of Virologic Response
Author(s) -
Nancy S. Shulman,
Andrew Zolopa,
D. J. Passaro,
Usha Murlidharan,
Dennis Israelski,
Carol Brosgart,
Michael D. Miller,
Sally Van Doren,
Robert W. Shafer,
David Katzenstein
Publication year - 2000
Publication title -
journal of acquired immune deficiency syndromes
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.162
H-Index - 157
eISSN - 1944-7884
pISSN - 1525-4135
DOI - 10.1097/00126334-200003010-00002
Subject(s) - adefovir , efavirenz , viral load , salvage therapy , reverse transcriptase inhibitor , virology , protease inhibitor (pharmacology) , medicine , drug resistance , retrospective cohort study , lentivirus , cohort , gastroenterology , biology , viral disease , antiretroviral therapy , human immunodeficiency virus (hiv) , lamivudine , virus , chemotherapy , chronic hepatitis , microbiology and biotechnology
To determine the impact of prior nonnucleoside reverse transcriptase inhibitor (NNRTI) therapy, genotypic resistance, and other variables on response to efavirenz (EFV)- and adefovir dipivoxil (ADV)-based salvage therapy.